Bright Minds Biosciences Inc (DRUG)
$75.00
$-2.47
(-3.19%)
As on 18-May-2026 16:00EDT
Market cap
$758 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
12.8
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.7
-
Face value
--
-
Shares outstanding
9,787,161
5 Years Aggregate
CFO
CA$-28.26 Mln
EBITDA
CA$-31.37 Mln
Net Profit
CA$-31.64 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bright Minds Biosciences Inc (DRUG)
| -3.9 | -16.6 | -10.6 | 127.3 | 199.7 | 24.7 | -- |
|
BSE Sensex*
| -11.2 | -4.2 | -10.2 | -8.7 | 7.0 | 8.4 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
|---|---|---|
|
Bright Minds Biosciences Inc (DRUG)
| 116.7 | -61.4 |
|
S&P Small-Cap 600
| 4.0 | 13.9 |
|
BSE Sensex
| 9.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bright Minds Biosciences Inc (DRUG)
|
75.0 | 758.2 | 0.0 | -19.8 | -- | -28.1 | -- | 12.8 |
| 5.2 | 413.1 | 0.0 | -131.6 | -- | -61.8 | -- | 1.0 | |
| 0.8 | 98.7 | 0.0 | -31.3 | -- | -- | -- | 1,055.0 |
Shareholding Pattern
View DetailsAbout Bright Minds Biosciences Inc (DRUG)
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for... epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York. Address: 19 Vestry Street, New York, NY, United States, 10013 Read more
-
Co-Founder, CEO, President & Director
Mr. Ian McDonald
-
Co-Founder, CEO, President & Director
Mr. Ian McDonald
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Bright Minds Biosciences Inc (DRUG)
What is the current share price of Bright Minds Biosciences Inc (DRUG) Today?
The share price of Bright Minds Biosciences Inc (DRUG) is $75.00 (NASDAQ) as of 18-May-2026 16:00 EDT. Bright Minds Biosciences Inc (DRUG) has given a return of 199.72% in the last 3 years.
What is the current PB & PE ratio of Bright Minds Biosciences Inc (DRUG)?
Since, TTM earnings of Bright Minds Biosciences Inc (DRUG) is negative, P/E ratio is not available.
The P/B ratio of Bright Minds Biosciences Inc (DRUG) is 12.81 times as on 18-May-2026, a 317 premium to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-34.72
|
5.18
|
|
2024
|
-1.67
|
0.85
|
|
2023
|
-0.87
|
0.97
|
|
2022
|
-0.16
|
0.23
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Bright Minds Biosciences Inc (DRUG)?
The 52-week high and low of Bright Minds Biosciences Inc (DRUG) are Rs 123.75 and Rs 23.18 as of 19-May-2026.
What is the market cap of Bright Minds Biosciences Inc (DRUG)?
Bright Minds Biosciences Inc (DRUG) has a market capitalisation of $ 758 Mln as on 18-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Bright Minds Biosciences Inc (DRUG)?
Before investing in Bright Minds Biosciences Inc (DRUG), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.